SYHA1813 vs Investigators' Choice as Treatment for Recurrent or Progressive High-Grade Meningioma: A Randomized, Controlled, Multicenter, Phase II Study
Latest Information Update: 24 Dec 2024
Price :
$35 *
At a glance
- Drugs SYHA 1813 (Primary)
- Indications Meningioma
- Focus Therapeutic Use
- Sponsors Shanghai Runshi Pharmaceutical
- 24 Dec 2024 New trial record